Tenax Therapeutics, INC 10-Q quarterly reports

Tenax Therapeutics reports increased R&D spending for Phase 3 trials of levosimendan, with cash reserves projected to fund operations through Q2 2028.

Tenax Therapeutics reports a significant increase in R&D expenses for Q1 2026, driven by ongoing Phase 3 trials for levosimendan, while extending its cash runway into early 2028.

Tenax Therapeutics reported a significant increase in net loss for Q3 and the nine months ended September 30, 2025, driven by expanded clinical trial activities and higher operating expenses, while maintaining sufficient cash for operations through 2027.

Tenax Therapeutics reported increased cash reserves and accelerated R&D spending to advance its Phase 3 levosimendan program for pulmonary hypertension, despite widening net losses.

Tenax Therapeutics reports increased operating expenses and net loss for Q1 2025, offset by a strong cash position following recent equity offerings.

Tenax Therapeutics reports a significant increase in cash and cash equivalents to $98.3 million following a $99.7 million private placement, enabling the company to fund operations through 2027.

Tenax Therapeutics reports increased research and development spending as it advances its Phase 3 clinical program for levosimendan, while also securing significant funding through a private placement.

Tenax Therapeutics reported a net loss of $3.8 million for the first quarter of 2024, while advancing its Phase 3 trial for oral levosimendan.